In addition to issues with the pandemic, the franchise was already faced with declining prices as well as headwind caused by a rebate from sales in Europe in the year-ago quarter.Excluding those and other issues, adjusted earnings per share were still down, coming in at $1.11, compared to $1.72 in the year-ago quarter, as Gilead increased spending on research and development to get its COVID-19 treatment, remdesivir, to market.